ClinicalTrials.gg
CompletedNCT06529796Updated Jan 20, 2025

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

A Phase 1 interventional study of IXP in Focal Segmental Glomerulosclerosis (FSGS), sponsored by Vertex Pharmaceuticals Incorporated. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States — 18 open to participants now, 21 under way, 2 of them phase 3. Glomerulosclerosis, Focal Segmental · United States.

Enrollment
21st of 56
36 · median 30
Started
2024
with 1 other
Phase 1
8 of 69
none open now
Registered
63rd of 69
by date
Lead sponsor
3 of 69
Vertex Pharmaceuticals Incorporated

Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, this one is the 21st largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 in phase 1, and was the 63rd registered.

Glomerulosclerosis, Focal Segmental

106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.

Browse Glomerulosclerosis, Focal Segmental studies →

Open to participants now

18 of the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger; 23 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of Inaxaplin (IXP) in participants with mild or moderate hepatic impairment and in matched healthy participants.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

03

Conditions studied

  • Focal Segmental Glomerulosclerosis (FSGS)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Cohorts 1 and 3: Participants with Hepatic Impairment

    • Cohort 1 (mild impairment): defined as a total score of 5 to 6 (Child-Pugh Class A)
    • Cohort 3 (moderate impairment): defined as a Child-Pugh total score of 7 to 9 (Child-Pugh Class B)
  • Cohorts 2 and 4: Healthy Participants

    • Participants will be matched during screening to participants with mild (Cohort 1) or moderate (Cohort 3) hepatic impairment according to each of the following parameters: age (± 10 years); sex; and (± 15%)

Key Exclusion Criteria:

  • Cohorts 1 and 3: Participants with Hepatic Impairment

    • Acute febrile illness within 14 days and/or acute illness within 5 days before first dose of study drug
    • Participants who smoke
  • Cohorts 2 and 4: Healthy Participants

    • Acute febrile illness within 14 days and/or acute illness within 5 days before first dose of study drug
    • Any condition possibly affecting drug absorption

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1: Mild Hepatic Impairment

    Participants will receive a single dose of IXP on Day 1.

    Drug: IXP

  • Experimental
    Cohort 2: Matched Healthy Participants

    Healthy participants matched to Cohort 1 will receive a single dose of IXP on Day 1.

    Drug: IXP

  • Experimental
    Cohort 3: Moderate Hepatic Impairment

    Participants will receive a single dose of IXP on Day 1.

    Drug: IXP

  • Experimental
    Cohort 4: Matched Healthy Participants

    Healthy participants matched to Cohort 3 will receive a single dose of IXP on Day 1.

    Drug: IXP

Interventions

  • DrugIXP

    Tablet for oral administration.

    Also known as: VX-147, Inaxaplin

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of IXP

    Time frame: From Day 1 up to Day 10

  2. Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of IXP

    Time frame: From Day 1 up to Day 10

Secondary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 20

07

Study locations

3 sites
  • Division of Clinical Pharmacology, University of Miami
    Miami, Florida 33136, United States
  • GCP Research
    Saint Petersburg, Florida 33705, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Dec 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2024
First posted
Jul 31, 2024
StartActual
Aug 2, 2024
Primary completionActual
Dec 20, 2024
CompletionActual
Dec 20, 2024
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06529796
Responsible party
Sponsor
First posted
Jul 31, 2024
Start date
Aug 2, 2024
Primary completion
Dec 20, 2024
Completion
Dec 20, 2024
Last update
Jan 20, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inaxaplin

Start the discussion